Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04563702 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
A Phase 1 study of Covid19, sponsored by Vaxart.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT04563702 is a Phase 1 study of Covid19 that has completed, run by Vaxart. The registered enrollment target is 35 participants, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04563702, a Phase 1 study of Covid19, has completed, sponsored by Vaxart.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to evaluate the safety and immunogenicity of VXA-CoV2-1 vaccine with repeat dosing at multiple dose levels. Safety and immunogenicity will be evaluated for up to 12 months after the second dose of VXA-CoV2-1.
Conditions Studied
Interventions
- BIOLOGICAL VXA-CoV2-1
Study Locations (1)
California
- WCCT - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-09-21 |
| Est. Completion | 2021-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04563702
The ClinicalTrials.gov registry entry for NCT04563702 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (99% lower). The listed sponsor is Vaxart, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 1 intervention - of which VXA-CoV2-1 is the first listed.
NCT04563702 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04563702 about?
NCT04563702 is a clinical study titled "Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects". VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to evaluate the safety and immunogenicity of VXA-CoV2-1 vaccine with...
What is the current status of trial NCT04563702?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2020-09-21. Estimated completion is 2021-10-10.
What conditions does trial NCT04563702 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT04563702?
The interventions under investigation include: VXA-CoV2-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04563702?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04563702 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MRI of Survivors of COVID-19
ACTIVE NOT RECRUITING · Phase 1
-
Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19
COMPLETED · Phase 1
-
RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19
COMPLETED · Phase 1
-
Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection
COMPLETED · Phase 1
-
COVID-19 Study of Safety and Tolerability of Alvelestat
COMPLETED · Phase 1
-
Electrical Stimulation for Critically Ill Covid-19 Patients
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.